| Merck and Schering-Plough to Complete Merger Today | | November 03, 2009 |
|
| Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C | | November 02, 2009 |
|
| Schering-Plough Announces Sponsorship of Rabies-Control Projects in India | | |
|
| Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies | | |
|
| Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting | | November 01, 2009 |
|
| U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma | | October 30, 2009 |
|
| Merck and Schering-Plough Receive Approvals From U.S. Federal Trade Commission, Swiss Competition Commission and Canadian Competition Bureau for Merger | | October 29, 2009 |
|
| Merck and Schering-Plough Receive Approval From European Commission for Merger | | October 23, 2009 |
|
| Schering-Plough Reports Financial Results for 2009 Third Quarter | | October 22, 2009 |
|
| Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and PEGINTRON(R) Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting | | October 15, 2009 |
|
| Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Concept Study | | October 13, 2009 |
|
| Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings | | October 12, 2009 |
|
| Intervet/Schering-Plough Animal Health Announces Sponsorship Supporting Milk Producers In Malawi | | October 08, 2009 |
|
| SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector | | October 06, 2009 |
|
| FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma | | October 05, 2009 |
|
| Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock | | September 18, 2009 |
|
| Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients | | September 14, 2009 |
|
| Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study | | |
|
| Three Directors Set For Newly-Combined Merck | | September 03, 2009 |
|
| Dieter Lutticken Award 2008 for Alternatives in Animal Testing Presented to Dr. Ivo Claassen (The Netherlands) | | |
|
| New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day | | September 01, 2009 |
|
| Merck CEO Announces Structure and Global Leadership Team for New Merck | | August 31, 2009 |
|
| Schering-Plough Announces Two European Filings | | August 26, 2009 |
|
| Video:Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults | | August 14, 2009 |
|
| Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) | | August 11, 2009 |
|
| Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours | | |
|
| Schering-Plough Shareholders Approve Merger With Merck | | August 07, 2009 |
|
| Schering-Plough to Webcast Special Meeting of Shareholders | | August 06, 2009 |
|
| Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN(R) (ezetimibe/simvastatin) and ZETIA(R) (ezetimibe) | | August 05, 2009 |
|
| FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia | | July 30, 2009 |
|
| Sanofi-aventis to Acquire Merck's Interest in Merial | | |
|
| SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia | | July 24, 2009 |
|
| Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck | | |
|
| Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma | | July 22, 2009 |
|
| Schering-Plough Reports Financial Results for 2009 Second Quarter | | July 21, 2009 |
|
| Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV | | July 15, 2009 |
|
| Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN(R) (ezetimibe/simvastatin) and ZETIA(R) (ezetimibe) | | |
|
| REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients | | July 09, 2009 |
|
| ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients | | |
|
| Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa | | July 01, 2009 |
|
| Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings | | June 29, 2009 |
|
| SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis | | June 26, 2009 |
|
| New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus | | June 23, 2009 |
|
| Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock | | |
|
| Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger | | June 22, 2009 |
|
| The New York Yankees' Mark Teixeira, National Foundation For Cancer Research, and the Makers of COPPERTONE SPORT(R) Launch 'Help Strike Out Sun Damage' Program | | June 17, 2009 |
|
| New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives | | June 10, 2009 |
|
| New Analysis Shows Efficacy of Simponi™ (GOLIMUMAB) in Anti-TNF Experienced Rheumatoid Arthritis Patients | | |
|
| Two-Year Data Show Patients Receiving Simponi™ (GOLIMUMAB) Experienced Sustained Improvements in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondyitis | | |
|
| Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder | | June 02, 2009 |
|
| Schering-Plough and Merck Provide Update on Distribution Agreement | | May 27, 2009 |
|
| Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males | | May 19, 2009 |
|
| Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD | | |
|
| Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair | | May 14, 2009 |
|
| Schering-Plough Schedules Webcast For Annual Meeting of Shareholders | | May 11, 2009 |
|
| Schering-Plough Starts Patient Enrollment in Phase 3 Trial for Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery | | |
|
| Schering-Plough Flips the Switch on 1.7 MW Rooftop Solar Panel System, One of the Largest in N.J., North America | | April 29, 2009 |
|
| Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting | | April 27, 2009 |
|
| Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients | | April 23, 2009 |
|
| Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality | | April 22, 2009 |
|
| Schering-Plough Reports Financial Results for 2009 First Quarter | | April 21, 2009 |
|
| Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis | | April 13, 2009 |
|
| Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay | | April 07, 2009 |
|
| Schering-Plough Announces Results of the Early ACS Trial | | March 30, 2009 |
|
| EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year | | |
|
| Video: New Children's Storybook Helps Parents Teach Their Children With Asthma About Their Condition | | March 24, 2009 |
|
| Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM) | | March 18, 2009 |
|
| Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development | | March 13, 2009 |
|
| Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study | | March 12, 2009 |
|
| Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings | | |
|
| FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C | | March 11, 2009 |
|
| Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference | | March 09, 2009 |
|
| Merck and Schering-Plough to Merge | | |
|
| Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference | | March 05, 2009 |
|
| European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors | | |
|
| Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France | | March 03, 2009 |
|
| Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock | | February 27, 2009 |
|
| Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries | | February 23, 2009 |
|
| Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder | | February 20, 2009 |
|
| Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards | | February 12, 2009 |
|
| Schering-Plough Reports Financial Results for 2008 Fourth Quarter, Full Year | | February 03, 2009 |
|
| Brooke Shields and the Makers of COPPERTONE(R) Join Together to Launch COPPERTONE(R) NutraShield(TM) - New Sunscreen Contains Antioxidants That Promote Natural Skin Repair | | January 27, 2009 |
|
| Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients | | |
|
| New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available | | January 14, 2009 |
|
| U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder | | |
|
| Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference | | January 09, 2009 |
|
| Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings | | January 06, 2009 |
|
